Journals / Turkish Journal of Gastroenterology / 2007 / Cilt: 18 - Sayı: 4

Akut hepatit C'ye eşlik eden akut perikarditin pegile interferon ile tedavisi

Pegylated interferon treatment of acute pericarditis associated with acute hepatitis C

Pages
268–271
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We conclude that pegylated interferon may be offered to patients with symptomatic acute HCV-related pericarditis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:65-year-old female patient was admitted to our hospital with the symptoms of chest pain, dyspnea and fatigue.
📊
Key Findings & Data:The serum alanine aminotransferase (ALT) at presentation was 650 IU/L and aspartate aminotransferase (AST) was 600 IU/L.
💡
Conclusion & Impact:We conclude that pegylated interferon may be offered to patients with symptomatic acute HCV-related pericarditis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Hepatit C · Antiviral ajanlar · Akut hastalık

Abstract

65-year-old female patient was admitted to our hospital with the symptoms of chest pain, dyspnea and fatigue. She had undergone a tooth extraction three months before. She took no medication. Echocardiography revealed pericardial effusion. The serum alanine aminotransferase (ALT) at presentation was 650 IU/L and aspartate aminotransferase (AST) was 600 IU/L. Hepatitis C virus (HCV) RNA level was 150,000 IU/ml. Genotype was 1b. Acute pericarditis was considered to be caused by acute HCV infection. The patient was followed without treatment. One month later, AST and ALT were found as 65 IU/L and 82 IU/L, respectively; there were symptoms of effort dyspnea and fatigue. Echocardiography showed minimal decrease in pericardial effusion compared to one month previously. HCV RNA level was again checked and found as 155,000 IU/ml. The patient was given pegylated interferon. One month later, the pericardial effusion and related symptoms had disappeared. The pegylated interferon treatment was sustained for 24 weeks and HCV-RNA was found negative at the 3rd and 6th months of the treatment and six months after the end of treatment. We conclude that pegylated interferon may be offered to patients with symptomatic acute HCV-related pericarditis.

Özet

Altmışbeş yaşında bayan hasta göğüs ağrısı, dispne ve yorgunluk şikayetleriyle kliniğimize başvurdu. Hikayesinde başvurudan 3 ay önce diş çekimi hikayesi vardı. Hastanın herhangi bir ilaç kullanımı yoktu. Ekokardiyografide perikardiyal effüzyon saptandı. İlk değerlendirmede alanin aminotrasferaz (ALT) düzeyi 650 IU/L, aspartat aminotransferaz (AST) düzeyi ise 600 IU/L saptandı. Hepatit C virüsü (HCV) RNA'sının kantitatif değeri 150.000 IU/mL bulundu. HCV'nün genotipi 1b idi. Akut perikardite sebep olan etiyolojik faktör olarak akut HCV infeksiyonu düşünüldü. Hasta tedavisiz izleme alındı. Takibin 1. ayında, AST ve ALT düzeyleri sırasıyla 65 IU/L ve 82 IU/L olarak bulundu. Hastanın efor dispnesi ve halsizlik şikayetleri devam etmekteydi. Kontrol ekokardiyografide perikardiyal efüzyonda minimal azalma mevcuttu. HCV RNA düzeyine tekrar bakıldı ve 155.000 IU/L bulundu. Hastaya pegile interferon tedavisi başlandı. Tedavinin 1. ayında yapılan kontrolde perikardiyal efüzyonun ve ilgili semptomların kaybolduğu görüldü. Pegile interferon tedavisine 24 hafta devam edildi. Tedavinin 3., 6. aylarında ve tedavi bitiminden 6 ay sonra yapılan kontrollerde HCV RNA düzeyleri negatif bulundu. Sonuç olarak, akut HCV infeksiyonuna sekonder gelişen semptomatik akut perikarditin tedavisinde pegile interferon kullanı labilir.

🔖

Cite This Article

KOCAMANİ, O., AYGÜN, C., KONDUK, B. T., ÇELEBİ, A., ŞENTÜRK, Ö., HÜLAGÜ, S. (2007). Akut hepatit C'ye eşlik eden akut perikarditin pegile interferon ile tedavisi. Turkish Journal of Gastroenterology, Cilt: 18 - Sayı: 4, 268–271. https://ajindex.com/articles/411422

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Imazio M, Trinchero R. Clinical management of acute pericardial disease: a review of results and outcomes. Ital Heart J 2004; 5: 803-17
  2. Narita H, Ohte N, Yoneyama A, et al. Takayasu's arteritis accompanied with massive pericardial effusion- a case report. Angiology 1999; 50: 421-5
  3. Clifford BD, Donahue D, Smith L, et al. The prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21: 613-9
  4. Scotto G, Palumbo E, Fazio V, et al. Peginterferon alfa-2b treatment for patients affected by acute hepatitis C: presentation of six case reports. Infection 2005; 33: 30-2
  5. Karlsen AE, Dyrberg T. Molecular mimicry between nonself, modified self and self in autoimmunity. Semin Immunol 1998; 10: 25-32
  6. Tomer Y, Davies TF. Infection, thyroid disease and autoimmunity. Endocrin Rev 1993; 14: 107-20
  7. Tomer Y, Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocrin Rev 2003; 24: 694-717
  8. Spodick DH. Low voltage with pericardial effusion: complexity of mechanisms. Chest 2003; 124: 2044-5
  9. Dolganiuc A, Oak S, Kodys K, et al. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 2004; 127: 1513-24
  10. Goyle KK, Walling AD. Diagnosing pericarditis. Am Fam Physician 2002; 66: 1695-702
  11. Wiegand J, Buggisch P, Boecher W, et al. German HEPNET Acute HCV Study Group. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 2006; 43: 221-4.